Gland Pharma’s Pashamylaram facility receives EU GMP certification from Denmark for aseptic powder injection, infusion, and inhalation.

• Certification covers marketing authorizations for non-EEA manufacturers, boosting export prospects to European markets.
• Facility approval enhances compliance credibility and supports growth in regulated markets.
• Products include aseptically prepared powder for injection, infusion, and inhalation therapies.